Altered Platelet Monoamine Oxidase-B Activity in Idiopathic Parkinson's Disease

Overview

Journal Neurochem Res

Specialties Chemistry
Neurology

Date 2009 Mar 5

PMID 19259810

Citations 3

Authors

Maroof Husain

Rakesh Shukla

Madhu Dikshit

Pradeep K Maheshwari

Devika Nag

Rikhab C Srimal

Prahlad K Seth

Vinay K Khanna

Affiliations

Soon will be listed here.

Abstract

A case-control study was undertaken to investigate the status of platelet monoamine oxidase-B (MAO-B) activity in Indian cases of idiopathic Parkinson's disease. A significant increase in the activity of platelet MAO-B was observed in Parkinson's cases (n = 26) as compared to controls (n = 26). No significant change in the activity of the enzyme was observed while the data was analysed with respect to age, sex and duration of disease. A trend of decrease in platelet MAO-B activity was observed in Parkinson's cases with respect to stage although the change was not significant. No correlation in platelet MAO-B activity was observed with respect to age and sex in the control subjects. Parkinson's cases treated with L-DOPA and MAO-B inhibitor exhibited decreased platelet MAO-B activity as compared to drug naive cases and those treated with L-DOPA alone. Interestingly, Parkinson's cases treated with L-DOPA and amantadine also had lower platelet MAO-B activity as compared to drug naive cases and those treated with L-DOPA alone. Activity of platelet MAO-B in Parkinson's patients was increased in naive cases and those treated with L-DOPA alone or in combination with other drugs compared to controls. The results of the present study indicate that phenotypic activity of platelet MAO-B is high in Indian Parkinson's cases. Further, action mechanism of drugs used in the treatment of Parkinson's disease could be understood by assay of platelet MAO-B activity. It is an interesting observation and may be looked further in large number of cases.

Citing Articles

The Systemic Immune-Inflammation Index and the Risk of Parkinson's Disease in the U.S.: A Cross-Sectional Study.

Liu F, Ran Q, Zhang H, Chen J J Clin Med. 2025; 14(2).

PMID: 39860410 PMC: 11765590. DOI: 10.3390/jcm14020403.

Crif1 deficiency in dopamine neurons triggers early-onset parkinsonism.

Heo J, Park A, Lee M, Ryu M, Kim Y, Jang Y Mol Psychiatry. 2023; 28(10):4474-4484.

PMID: 37648779 DOI: 10.1038/s41380-023-02234-5.

Beyond Haemostasis and Thrombosis: Platelets in Depression and Its Co-Morbidities.

Izzi B, Tirozzi A, Cerletti C, Donati M, de Gaetano G, Hoylaerts M Int J Mol Sci. 2020; 21(22).

PMID: 33233416 PMC: 7700239. DOI: 10.3390/ijms21228817.

Platelets in Neurodegenerative Conditions-Friend or Foe?.

Leiter O, Walker T Front Immunol. 2020; 11:747.

PMID: 32431701 PMC: 7214916. DOI: 10.3389/fimmu.2020.00747.

References

Lai B, Marion S, Teschke K, Tsui J . Occupational and environmental risk factors for Parkinson's disease. Parkinsonism Relat Disord. 2004; 8(5):297-309. DOI: 10.1016/s1353-8020(01)00054-2. View

Steventon G, Humfrey C, Sturman S, Waring R, Williams A . Monoamine oxidase B and Parkinson's disease. Lancet. 1990; 335(8682):180. DOI: 10.1016/0140-6736(90)90063-b. View

Parsian A, Racette B, Zhang Z, Rundle M, Perlmutter J . Association of variations in monoamine oxidases A and B with Parkinson's disease subgroups. Genomics. 2004; 83(3):454-60. DOI: 10.1016/j.ygeno.2003.09.002. View

Coyle J, Puttfarcken P . Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993; 262(5134):689-95. DOI: 10.1126/science.7901908. View

Humfrey C, Steventon G, Sturman S, Waring R, Griffiths B, Williams A . Monoamine oxidase substrates in Parkinson's disease. Biochem Pharmacol. 1990; 40(11):2562-4. DOI: 10.1016/0006-2952(90)90101-p. View

Gorell J, Johnson C, Rybicki B, Peterson E, Richardson R . The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology. 1998; 50(5):1346-50. DOI: 10.1212/wnl.50.5.1346. View

Bonuccelli U, Piccini P, Del Dotto P, Pacifici G, Corsini G, MURATORIO A . Platelet monoamine oxidase B activity in parkinsonian patients. J Neurol Neurosurg Psychiatry. 1990; 53(10):854-5. PMC: 488245. DOI: 10.1136/jnnp.53.10.854. View

Hernan M, Checkoway H, OBrien R, Costa-Mallen P, De Vivo I, Colditz G . MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD. Neurology. 2002; 58(9):1381-7. DOI: 10.1212/wnl.58.9.1381. View

Kochersperger L, Parker E, Siciliano M, Darlington G, Denney R . Assignment of genes for human monoamine oxidases A and B to the X chromosome. J Neurosci Res. 1986; 16(4):601-16. DOI: 10.1002/jnr.490160403. View

10.

Calne D, Snow B, Lee C . Criteria for diagnosing Parkinson's disease. Ann Neurol. 1992; 32 Suppl:S125-7. DOI: 10.1002/ana.410320721. View

11.

Kuhn W, Muller T, Gerstner A, Winkel R, Goetz M . Platelet monoamine oxidase B activity in "de novo" and l-dopa treated parkinsonian patients and controls. Can J Neurol Sci. 1998; 25(3):249-51. DOI: 10.1017/s0317167100034090. View

12.

Veral A, Alper G, Mentes G, Ersoz B . Age and sex related alterations in serum and platelet monoamine oxidase. Eur J Clin Chem Clin Biochem. 1997; 35(4):265-8. DOI: 10.1515/cclm.1997.35.4.265. View

13.

Paterson I, Juorio A, Berry M, Zhu M . Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum. J Pharmacol Exp Ther. 1991; 258(3):1019-26. View

14.

Caramona M, Cotrim M, Ribeiro C, Macedo T . Monoamine oxidase activity in blood platelets of migraine patients. J Neural Transm Suppl. 1990; 32:161-4. DOI: 10.1007/978-3-7091-9113-2_23. View

15.

Diaz-Marsa M, Carrasco J, Hollander E, Cesar J, Saiz-Ruiz J . Decreased platelet monoamine oxidase activity in female anorexia nervosa. Acta Psychiatr Scand. 2000; 101(3):226-30. View

16.

Menegon A, Board P, Blackburn A, Mellick G, Le Couteur D . Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet. 1998; 352(9137):1344-6. DOI: 10.1016/s0140-6736(98)03453-9. View

17.

Danielczyk W, STREIFLER M, Konradi C, Riederer P, Moll G . Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia. Acta Psychiatr Scand. 1988; 78(6):730-6. DOI: 10.1111/j.1600-0447.1988.tb06412.x. View

18.

HOEHN M, Yahr M . Parkinsonism: onset, progression and mortality. Neurology. 1967; 17(5):427-42. DOI: 10.1212/wnl.17.5.427. View

19.

Pedersen N, Oreland L, Reynolds C, McClearn G . Importance of genetic effects for monoamine oxidase activity in thrombocytes in twins reared apart and twins reared together. Psychiatry Res. 1993; 46(3):239-51. DOI: 10.1016/0165-1781(93)90092-u. View

20.

Jarman J, Glover V, Sandler M, Turjanski N, Stern G . Platelet monoamine oxidase B activity in Parkinson's disease: a re-evaluation. J Neural Transm Park Dis Dement Sect. 1993; 5(1):1-4. DOI: 10.1007/BF02260909. View